Fuzuloparib as Maintenance Therapy is Effective Regardless of BRCA 1/2 Mutation
16460
post-template-default,single,single-post,postid-16460,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Fuzuloparib as Maintenance Therapy is Effective Regardless of BRCA 1/2 Mutation

Home > Blogs  > Fuzuloparib as Maintenance Therapy is Effective Regardless of BRCA 1/2 Mutation

23 Apr Fuzuloparib as Maintenance Therapy is Effective Regardless of BRCA 1/2 Mutation

Posted at 10:42h in Blogs by

In patients with platinum-sensitive, recurrent ovarian cancer previously treated with at least two platinum-based regimens, Fuzuloparib as a maintenance therapy showed a significantly improved progression-free survival compared with placebo, regardless of germline BRCA 1/2 mutation. (Ref: Li N et al. J Clin Oncol. April 11, 2022)
#oncologyresearch #clinicaldevelopment

https://www.linkedin.com/feed/update/urn:li:activity:6923581090574000128

No Comments

Sorry, the comment form is closed at this time.